Entasis Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Entasis Therapeutics Holdings (NASDAQ: ETTX) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entasis Therapeutics Holdings (NASDAQ: ETTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company will host a fireside chat available on-demand starting September 13 at 7:00 AM ET, alongside one-on-one investor meetings. Entasis focuses on developing novel antibacterial products targeting serious infections from multidrug-resistant Gram-negative bacteria, featuring a robust pipeline, including treatments for Acinetobacter baumannii and Neisseria gonorrhoeae.
Details
News Market Reaction – ETTX
The recorded move for ETTX in the trading session of this news was -5.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming H.C. Wainwright 23rd Annual Global Investment Conference. Details of the Company’s participation are as follows:
| Conference: H.C. Wainwright 23rd Annual Global Investment Conference | |
| Dates: September 13-15, 2021 | |
| Format: | Fireside chat available on-demand beginning September 13th at 7:00am ET |
| One-on-one investor meetings | |
About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.
Entasis Contacts
Company:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com
Investor Relations:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
bmackle@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.